IHAM
KYMR icon

Integral Health Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Integral Health Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$2.5M – 82
2022
Q4 		$2.5M Buy
+100,000
New +$2.67M 0.52% 53

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Integral Health Asset Management's KYMR Position: Q1 2023 in Review

Integral Health Asset Management sold out of Kymera Therapeutics (KYMR) in Q1 2023, closing a stake of 100,000 shares — an estimated $2.5M sold.

Integral Health Asset Management first reported a position in KYMR in Q4 2022 and held it in 1 quarter. The position peaked at $2.5M in Q4 2022. 127 funds tracked by Wall St. Rank hold KYMR as of Q1 2023.

  • Integral Health Asset Management reported no remaining Kymera Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Integral Health Asset Management sold 100,000 Kymera Therapeutics shares in Q1 2023, an estimated $2.5M.
  • Integral Health Asset Management first reported a position in Kymera Therapeutics in Q4 2022 and held it in 1 quarter.
  • Integral Health Asset Management's Kymera Therapeutics position peaked at $2.5M in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2023.

Based on Integral Health Asset Management's 13F filing for Q1 2023, filed 9 May 2023.